CD40LG and head and neck squamous cell carcinoma: In a study involving 60 HNSCC patients treated with nivolumab, patients with CR/PR/SD > 6 months had a lower percentage of unswitched B cells (CD21+CD27+IgM+IgD+) and a higher percentage of plasmablasts (CD38++IgM-) at baseline [145].